NCT05718687View on ClinicalTrials.gov

A GBT021601 ADME Microtracer Study in Healthy Volunteers

PHASE1CompletedINTERVENTIONAL
Enrollment

9

Participants

Timeline

Start Date

December 22, 2022

Primary Completion Date

August 10, 2023

Study Completion Date

August 10, 2023

Conditions
Sickle Cell Disease
Interventions
DRUG

GBT021601

Single oral dose of 200 mg GBT021601, containing \~74 kBq (\~2 µCi) of \[14C\]-GBT021601

Trial Locations (1)

9728

ICON Early Phase Clinic, LLC, Groningen

Sponsors

Lead Sponsor

Pfizer
All Listed Sponsors
lead

Pfizer

INDUSTRY

NCT05718687 - A GBT021601 ADME Microtracer Study in Healthy Volunteers | Biotech Hunter | Biotech Hunter